SoftBank has contributed to a $350m private placement supporting the health screening provider’s reverse takeover.
Author: Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Kriya Therapeutics engineers $100m series B
Patient Square Capital led a series B round for the gene therapy developer that included existing corporate investor Dexcel Pharma.
Mobilion makes a mark with $60m
Existing investor Agilent helped the biomedical analysis technology developer close a series C round that pushed its overall funding past $110m.
Icosavax initiates IPO procedure
The Sanofi-backed vaccine developer has filed to float on the Nasdaq Global Select Market and set a placeholder target of $100m.
Muna makes way to $73m series A
Novo and Sanofi Ventures both participated in a series A round for the neurodegenrative disease drug developer, which is led by EIRs at Novo Seeds.
Squirrel AI gathers series C1 funding
SIG returned to reinvest in the online education platform developer, which achieved unicorn status three years ago.
Bestmile runs out of steam
The fleet management technology provider is winding down following some $33m in funding from investors including Airbus Ventures and Groupe ADP.
Inflowmatix slides into Suez Group
Suez Group has paid an undisclosed amount for water flow analytics provider Inflowmatix after investing $3.4m in the company in 2019.
Boston Scientific bonds with Farapulse for $295m
Long-term investor Boston Scientific is paying $295m upfront for the 73% of the ablation technology developer it does not own.
Motif FoodWorks makes $226m series B move
Motif FoodWorks, launched by Gingko Bioworks, has pocketed $226m in a round backed by returning investor Louis Dreyfus a month after Gingko agreed to a reverse merger.
Umoja draws on SoftBank for $210m
SoftBank Vision Fund 2 co-led a series B round for immunotherapy developer Umoja Biopharma with Cormorant Asset Management.
Apollo assembles investors for $145m round
The Johnson & Johnson, GSK and AstraZeneca-backed drug developer raised the cash in a Patient Square Capital-led round that took its total funding beyond $200m.
Rev1 revisits corporates for $20m Fund II
Worthington Industries, Cardinal Health, Dispatch Printing, Nationwide and AEP Ohio are among the vehicle’s limited partners.
Origami Energy folds in new funding
Barclays Sustainable Impact Capital led a $28.5m round for the energy management software provider that included existing investor Aggreko.